The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Non-Invasive Vagus Nerve Stimulation Tolerated, Effective for Rheumatoid Arthritis

Non-Invasive Vagus Nerve Stimulation Tolerated, Effective for Rheumatoid Arthritis

March 24, 2021 • By Lisa Rapaport

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters Health)—Non-invasive vagus nerve stimulation is safe and effective as an intervention for rheumatoid arthritis (RA), a small proof-of-concept study suggests.

You Might Also Like
  • Studies Probe Treating Rheumatoid Arthritis with Vagus Nerve Stimulation
  • Etanercept Biosimilar Is Effective, Well-Tolerated for Rheumatoid Arthritis
  • Baricitinib Effective for Treating Refractory Rheumatoid Arthritis

The study enrolled 35 patients with active RA and an inadequate response to therapy with disease-modifying anti-rheumatic drugs (DMARDs). All DMARDS were discontinued four weeks prior to the trial. For the study, all participants were asked to wear a non-invasive vagus nerve stimulation device for up to 30 minutes daily over the course of 12 weeks.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Participants had follow-up visits at weeks 1, 2, 4, 8 and 12; the primary endpoint was mean change in the Disease Activity Score of 28 joints with C-reactive protein (DAS28-CRP) from baseline to week 12.

The mean DAS28-CRP score was 1.4 points lower at week 12 than at baseline, when mean scores were 5.3, the study team reports in The Lancet Rheumatology. Eleven out of 30 participants (37%) had mean scores of 3.2 or less at the end of the study, and seven patients (23%) had mean scores below 2.6.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“The aim of non-invasive vagus nerve stimulation is to modulate a neurological pathway that helps control immune function,” says lead author Sara Marsal, MD, head of rheumatology at Vall d’Hebron University Hospital and an associate professor of rheumatology at the Autonomous University of Barcelona.

“In our clinical trial, this resulted in meaningful clinical improvement for patients that had failed conventional DMARDs,” Dr. Marsal says by email.

Overall, patients wore the device as directed on 94% of the study days. A total of 27 patients completed the study.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

There were four adverse events, including one superficial skin abrasion at the point of contact where the device touched the ear. The other three events didn’t appear to be related to the device, and no patients dropped out of the study due to side effects.

Two main limitations of the study are the small sample size and the open-label design, the authors note.

The results need to be reproduced in a larger group over a longer period of time using a placebo group and including patients refractory to pharmacological therapy, says Alexandre Kanashiro of the department of neuroscience and behavior at Ribeirao Preto Medical School, University of Sao Paulo, Brazil.

If additional studies do confirm the safety and effectiveness of this intervention, then “the use of this non-invasive technology would be really encouraging for the treatment of RA and other chronic inflammatory conditions,” Mr. Kanashiro, who wasn’t involved in the study, says by email.

Pages: 1 2 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: Rheumatoid Arthritis (RA), vagus nerve stimulation

You Might Also Like:
  • Studies Probe Treating Rheumatoid Arthritis with Vagus Nerve Stimulation
  • Etanercept Biosimilar Is Effective, Well-Tolerated for Rheumatoid Arthritis
  • Baricitinib Effective for Treating Refractory Rheumatoid Arthritis
  • Depression & Anxiety Linked to Poor Rheumatoid Arthritis Outcomes

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.